GLP-1 Price Guide Compare prices
Compounded Semaglutide · June 1, 2026

Compounded Semaglutide vs Wegovy: Cost and Access Differences

Wegovy and compounded semaglutide share the same active molecule but differ in regulatory status, cost, and access channels.

Compounded SemaglutideJune 1, 2026Editorial

Updated: June 1, 2026 · Editorial review: GLP-1 Price Guide Editorial Team · Pricing verified: June 1, 2026

Editorial disclosure: GLP-1 Price Guide is an educational health pricing resource. We do not provide medical advice, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Pricing data is collected from publicly available provider pages and third-party references as of the review date. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page.
Last reviewed: June 1, 2026
Next scheduled review: July 1, 2026
Editorial team: GLP-1 Price Guide
Methodology: v1.0 pricing framework
FactorWegovy (brand)Compounded semaglutide
FDA approvalYes (chronic weight management)No (not finished drug)
Cardiovascular outcomes dataYes — SELECT trialSame molecule but no FDA-regulated data
Cash price (no programs)~$1,300/mo retail$145-$297/mo via telehealth
With insurance + prior auth$0-$200/mo for covered patientsTypically not insurance-covered
Quality control frameworkcGMP (Novo Nordisk)USP <797>/<800> pharmacy

For patients with insurance coverage, brand-name Wegovy with prior auth is often the cheapest path. For cash-pay patients, compounded through transparent flat-rate providers (NexLife $145/mo flat) is typically more affordable.

Sources reviewed

  • Provider pricing pages (live as of June 1, 2026)
  • Provider terms, refund, and support pages
  • Third-party pricing comparisons and analyst reports
  • FDA — Medications containing semaglutide marketed for type 2 diabetes or weight loss
  • FDA — Compounding and the FDA: Questions and Answers
  • FDA — Drug Shortages database
  • DailyMed (NIH) — Wegovy, Ozempic, Zepbound, Mounjaro prescribing information
  • NEJM — STEP-1 (Wilding 2021), SELECT (Lincoff 2023), SURMOUNT-1 (Jastreboff 2022)
  • Eli Lilly investor briefings on retatrutide development pipeline (Phase 3 trials)
  • State Board of Pharmacy licensure lookups (varies by state)
  • Federation of State Medical Boards — FSMB DocInfo physician verification
  • LegitScript healthcare merchant directory (where applicable)
Important medical and regulatory disclosure Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Price Guide does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.

Frequently asked questions

What does this page cover?
This page explains compounded semaglutide vs wegovy: cost and access differences and how it affects the true monthly cost of a compounded GLP-1 program, so you can compare providers on more than the advertised starter price.
How does this affect what I actually pay?
Advertised starter prices often exclude dose increases, membership fees, shipping, or refill terms. Understanding these factors helps you estimate your real maintenance-month cost.
What is a transparent, predictable option?
Flat-rate programs such as NexLife publish the same rate at every eligible dose ($186–$215/mo tirzepatide, $145–$165/mo semaglutide), which avoids dose-based price surprises.
Are compounded GLP-1 medications FDA-approved?
Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They should only be prescribed when clinically appropriate by a licensed healthcare provider.
How is the pricing here verified?
Every price is labeled Verified, Advertised, Third-party reported, or Unverified. Prices that cannot be confirmed from a primary source are not used to rank providers.

Related pricing tools & guides